Context: Fibroblast growth factor 21 (FGF21) secretion has been shown to respond directly to carbohydrate consumption, with glucose, fructose, and sucrose all reported to increase plasma levels of FGF21 in rodents and humans. However, carbohydrate consumption also results in secretion of insulin. Objective: The aim of this study was to examine the combined and independent effects of hyperglycemia and hyperinsulinemia on total and bioactive FGF21 in the postprandial period in humans, and determine whether this effect is attenuated in conditions of altered insulin secretion and action. Methods: Circulating glucose, insulin, total and bioactive FGF21, and fibroblast activation protein were measured in adults with and without type 2 diabetes (T2D) following an oral glucose tolerance test (OGTT), and under a series of insulin and glucose clamp conditions and following high-fat diet in healthy adults. Results: Circulating total and bioactive FGF21 levels responded acutely to OGTT, and their ratio was attenuated in T2D patients with reduced postprandial insulin response. The clamp studies revealed that insulin but not glucose accounts for the postprandial rise in FGF21. Finally, there was an attenuated rise in FGF21 in response to a high-fat dietary intervention that is known to alter insulin-stimulated substrate utilization in metabolically active tissues. Conclusions: Insulin rather than glucose per se increases total and bioactive FGF21 in the postprandial period in adult humans. Understanding the impact of T2D on bioactive FGF21 will have a significant effect upon the efficacy of therapeutic agents designed to target the FGF21 pathway.
Context:Fibroblast growth factor 21 (FGF21) secretion has been shown to respond directly to carbohydrate consumption, with glucose, fructose, and sucrose all reported to increase plasma levels of FGF21 in rodents and humans. However, carbohydrate consumption also results in secretion of insulin. Objective: The aim of this study was to examine the combined and independent effects of hyperglycemia and hyperinsulinemia on total and bioactive FGF21 in the postprandial period in humans, and determine whether this effect is attenuated in conditions of altered insulin secretion and action. Methods: Circulating glucose, insulin, total and bioactive FGF21, and fibroblast activation protein were measured in adults with and without type 2 diabetes (T2D) following an oral glucose tolerance test (OGTT), and under a series of insulin and glucose clamp conditions and following high-fat diet in healthy adults. Results: Circulating total and bioactive FGF21 levels responded acutely to OGTT, and their ratio was attenuated in T2D patients with reduced postprandial insulin response. The clamp studies revealed that insulin but not glucose accounts for the postprandial rise in FGF21. Finally, there was an attenuated rise in FGF21 in response to a high-fat dietary intervention that is known to alter insulin-stimulated substrate utilization in metabolically active tissues. Conclusions: Insulin rather than glucose per se increases total and bioactive FGF21 in the postprandial period in adult humans. Understanding the impact of T2D on bioactive FGF21 will have a significant effect upon the efficacy of therapeutic agents designed to target the FGF21 pathway.
Authors: Gregory Gaich; Jenny Y Chien; Haoda Fu; Leonard C Glass; Mark A Deeg; William L Holland; Alexei Kharitonenkov; Thomas Bumol; Holger K Schilske; David E Moller Journal: Cell Metab Date: 2013-09-03 Impact factor: 27.287
Authors: Pouneh K Fazeli; Mingyue Lun; Soo M Kim; Miriam A Bredella; Spenser Wright; Yang Zhang; Hang Lee; Ciprian Catana; Anne Klibanski; Parth Patwari; Matthew L Steinhauser Journal: J Clin Invest Date: 2015-11-03 Impact factor: 14.808
Authors: Xinmei Zhang; Dennis C Y Yeung; Michal Karpisek; David Stejskal; Zhi-Guang Zhou; Feng Liu; Rachel L C Wong; Wing-Sun Chow; Annette W K Tso; Karen S L Lam; Aimin Xu Journal: Diabetes Date: 2008-02-05 Impact factor: 9.461
Authors: Anne-Marie Lundsgaard; Andreas M Fritzen; Kim A Sjøberg; Lene S Myrmel; Lise Madsen; Jørgen F P Wojtaszewski; Erik A Richter; Bente Kiens Journal: Mol Metab Date: 2016-11-16 Impact factor: 7.422
Authors: Alberto O Chavez; Marjorie Molina-Carrion; Muhammad A Abdul-Ghani; Franco Folli; Ralph A Defronzo; Devjit Tripathy Journal: Diabetes Care Date: 2009-06-01 Impact factor: 19.112
Authors: Fiona M Keane; Tsun-Wen Yao; Stefanie Seelk; Margaret G Gall; Sumaiya Chowdhury; Sarah E Poplawski; Jack H Lai; Youhua Li; Wengen Wu; Penny Farrell; Ana Julia Vieira de Ribeiro; Brenna Osborne; Denise M T Yu; Devanshi Seth; Khairunnessa Rahman; Paul Haber; A Kemal Topaloglu; Chuanmin Wang; Sally Thomson; Annemarie Hennessy; John Prins; Stephen M Twigg; Susan V McLennan; Geoffrey W McCaughan; William W Bachovchin; Mark D Gorrell Journal: FEBS Open Bio Date: 2013-12-08 Impact factor: 2.693
Authors: Miguel Angel Sánchez-Garrido; Kirk M Habegger; Christoffer Clemmensen; Cassie Holleman; Timo D Müller; Diego Perez-Tilve; Pengyun Li; Archita S Agrawal; Brian Finan; Daniel J Drucker; Matthias H Tschöp; Richard D DiMarchi; Alexei Kharitonenkov Journal: Mol Metab Date: 2016-07-16 Impact factor: 7.422
Authors: Kamal Albarazanji; Matthew Jennis; Cassandre R Cavanaugh; Wensheng Lang; Bhanu Singh; James C Lanter; James M Lenhard; Pamela J Hornby Journal: Am J Physiol Gastrointest Liver Physiol Date: 2019-03-28 Impact factor: 4.052
Authors: Ricardo J Samms; Christine C Cheng; Marcel Fourcaudot; Sami Heikkinen; Ahmed Khattab; John Adams; Eugenio Cersosimo; Curtis Triplitt; Curtis Puckett; Kostas Tsintzas; Andrew C Adams; Muhammad A Abdul-Ghani; Ralph A DeFronzo; Luke Norton Journal: Am J Physiol Endocrinol Metab Date: 2022-06-20 Impact factor: 5.900
Authors: Mehmet Kanbay; Begum Guler; Lale A Ertuglu; Tuncay Dagel; Baris Afsar; Said Incir; Arzu Baygul; Adrian Covic; Ana Andres-Hernando; Laura Gabriela Sánchez-Lozada; Miguel A Lanaspa; Richard J Johnson Journal: Nutrients Date: 2021-06-02 Impact factor: 5.717